We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilars Makers Press for Dose API as Reference Comparator
Biosimilars Makers Press for Dose API as Reference Comparator
Companies developing biosimilars for the European market want regulators to revert to comparing therapies with the reference product based on the amount of active ingredient in a dose, rather than a proposed standard that compares dose with route of administration.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor